Oncology Institute (NASDAQ:STLN) Trading Down 4.4% – Should You Sell?

Oncology Institute, Inc. (NASDAQ:STLN) was down 4.4% during trading on Thursday . The company traded as low as $6.19 and last traded at $6.27. 243,959 shares changed hands during mid-day trading, a decline of 87% from the average session volume of 1,868,538 shares. The stock had previously closed at $6.56.

Analysts Set New Price Targets

Separately, Weiss Ratings initiated coverage on Oncology Institute in a report on Thursday, August 6th. They set a “sell (d-)” rating on the stock. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Oncology Institute presently has an average rating of “Sell”.

Oncology Institute Stock Down 2.7%

The stock has a market cap of $609.84 million, a price-to-earnings ratio of -20.57 and a beta of 0.38.

Oncology Institute (NASDAQ:STLN) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.08) earnings per share for the quarter. The business had revenue of $161.28 million during the quarter, compared to the consensus estimate of $152.80 million. On average, research analysts predict that Oncology Institute, Inc. will post -0.21 EPS for the current year.

Insider Activity

In other news, major shareholder Jorey Chernett bought 12,000 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The stock was purchased at an average cost of $6.54 per share, with a total value of $78,480.00. Following the transaction, the insider directly owned 10,660,858 shares in the company, valued at $69,722,011.32. This trade represents a 0.11% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Brad Hively sold 298,853 shares of the stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $6.51, for a total value of $1,945,533.03. Following the completion of the sale, the director directly owned 411,976 shares of the company’s stock, valued at $2,681,963.76. The trade was a 42.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 4.40% of the company’s stock.

Institutional Trading of Oncology Institute

A hedge fund recently bought a new stake in Oncology Institute stock. AXQ Capital LP acquired a new position in shares of Oncology Institute, Inc. (NASDAQ:STLN) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 22,460 shares of the company’s stock, valued at approximately $122,000. Hedge funds and other institutional investors own 36.86% of the company’s stock.

About Oncology Institute

Oncology Institute is a physician-led healthcare company focused on delivering specialized cancer care through an integrated oncology platform. Its services are designed to support patients throughout the cancer-care journey, including diagnosis, treatment planning, chemotherapy and other medical oncology services, supportive care, and ongoing disease management.

The company’s business model emphasizes value-based oncology care, with care coordination and clinical programs intended to improve outcomes while managing the overall cost of treatment.